Guggenheim restated their buy rating on shares of Tarsus Pharmaceuticals (NASDAQ:TARS - Free Report) in a report issued on Monday morning,Benzinga reports.
A number of other research firms have also weighed in on TARS. Barclays raised their price objective on shares of Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the company an "overweight" rating in a research note on Monday, January 27th. Oppenheimer raised their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. Finally, The Goldman Sachs Group lifted their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a "neutral" rating in a research note on Friday, November 15th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $56.00.
Get Our Latest Analysis on TARS
Tarsus Pharmaceuticals Stock Down 0.7 %
Shares of NASDAQ:TARS traded down $0.39 during trading on Monday, reaching $51.94. 272,445 shares of the stock were exchanged, compared to its average volume of 633,101. Tarsus Pharmaceuticals has a 1-year low of $20.08 and a 1-year high of $57.28. The stock has a fifty day moving average of $52.06 and a two-hundred day moving average of $41.30. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. The firm has a market cap of $1.99 billion, a price-to-earnings ratio of -13.67 and a beta of 1.01.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Crowley Wealth Management Inc. purchased a new stake in Tarsus Pharmaceuticals in the 4th quarter valued at about $25,000. R Squared Ltd purchased a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter valued at approximately $53,000. FMR LLC increased its position in shares of Tarsus Pharmaceuticals by 236.6% during the third quarter. FMR LLC now owns 5,032 shares of the company's stock valued at $166,000 after acquiring an additional 3,537 shares during the last quarter. HighTower Advisors LLC bought a new stake in Tarsus Pharmaceuticals during the fourth quarter worth $207,000. Finally, Victory Capital Management Inc. bought a new position in Tarsus Pharmaceuticals in the 4th quarter valued at $223,000. 90.01% of the stock is currently owned by hedge funds and other institutional investors.
About Tarsus Pharmaceuticals
(
Get Free Report)
Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
Further Reading
Before you consider Tarsus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tarsus Pharmaceuticals wasn't on the list.
While Tarsus Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
